UBS Group
CCEL icon

UBS Group’s Cryo-Cell International CCEL Stock Holding History

UBS Group’s Portfolio CCEL Stock Details CCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.39K Buy
672
+459
+215% +$1.53K ﹤0.01% 9288
2025
Q4 		$733 Buy
213
+82
+63% +$340 ﹤0.01% 9833
2025
Q3 		$608 Buy
131
+31
+31% +$147 ﹤0.01% 9603
2025
Q2 		$519 Sell
100
-1,396
-93% -$7.36K ﹤0.01% 9806
2025
Q1 		$9.53K Sell
1,496
-1,652
-52% -$12K ﹤0.01% 8685
2024
Q4 		$23.3K Buy
3,148
+2,899
+1,164% +$21.9K ﹤0.01% 7778
2024
Q3 		$1.59K Buy
+249
New +$1.72K ﹤0.01% 8600
2024
Q1 		– Sell
-741
Closed -$4.26K – 9376
2023
Q4 		$4.26K Buy
+741
New +$3.84K ﹤0.01% 7887
2023
Q2 		– Sell
-177
Closed -$535 – 8975
2023
Q1 		$535 Sell
177
-1,547
-90% -$5.97K ﹤0.01% 8983
2022
Q4 		$7.29K Buy
1,724
+1,587
+1,158% +$7.6K ﹤0.01% 8914
2022
Q3 		$1K Sell
137
-132
-49% -$814 ﹤0.01% 9933
2022
Q2 		$2K Sell
269
-1,160
-81% -$7.42K ﹤0.01% 9516
2022
Q1 		$11K Buy
1,429
+1,425
+35,625% +$13.1K ﹤0.01% 8286
2021
Q4 		$0 Sell
4
-148
-97% -$1.84K ﹤0.01% 10277
2021
Q3 		$2K Buy
+152
New +$1.87K ﹤0.01% 8932

Other funds holding CCEL

SA
SFI Advisors Montclair, New Jersey $95.2M AUM 23.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

UBS Group's CCEL Position: Q1 2026 in Review

UBS Group increased its Cryo-Cell International (CCEL) stake by 215% in Q1 2026, buying an estimated $1.53K and bringing the position to 672 shares worth $2.39K. The position accounts for ﹤0.01% of the portfolio, ranked #9288.

UBS Group first reported a position in CCEL in Q3 2021 and has held it in 15 quarters since. The position peaked at $23.3K in Q4 2024. 11 funds tracked by Wall St. Rank hold CCEL as of Q1 2026.

  • UBS Group held 672 shares of Cryo-Cell International worth $2.39K as of Q1 2026.
  • UBS Group bought 459 Cryo-Cell International shares in Q1 2026, an estimated $1.53K.
  • Cryo-Cell International made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9288 holding.
  • UBS Group first reported a position in Cryo-Cell International in Q3 2021 and has held it in 15 quarters since.
  • UBS Group's Cryo-Cell International position peaked at $23.3K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Cryo-Cell International as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.